Press Releases

11:07am Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution EQ
22/01 Bayer : FDA grants Orphan Drug Designation to BlueRock Therapeutics’ investigational cell therapy OpCT-001 PU
21/01 Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution EQ
20/01 Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution EQ
20/01 Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases BU
17/01 Bayer welcomes the U.S. Supreme Court decision to review the Durnell case in the Roundup™ litigation BU
17/01 Bayer : welcomes the U.S. Supreme Court decision to review the Durnell case in the Roundup™ litigation PU
16/01 Bayer : Eylea™ 8 mg approved in the EU for third retinal indication PU
14/01 Bayer Accelerates Pharma Growth on High-Value Portfolio BU
13/01 Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn’t Stop for a Hot Flash’ Campaign for Moderate to Severe Hot Flashes Due to Menopause BU
12/01 Bayer to Expand Into Molecular Imaging With Acquisition of Innovative Pan-Amyloid Radiotracers From Attralus BU
12/01 Bayer : to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus PU
08/01 Bayer : to launch innovative strawberry variety PU
08/01 Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy BU
06/01 Bayer : receives Breakthrough Therapy Designation in the U.S. and China for sevabertinib as a first-line treatment for patients with HER2-mutant non-small cell lung cancer PU
05/01 Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan’s 44th Annual Healthcare Conference BU
05/01 Bayer : to present updates on pharma growth strategy and pipeline advancements at J.P. Morgan’s 44th Annual Healthcare Conference PU
29/12 Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution EQ
22/12 Bayer : Finerenone approved in Japan for treatment of patients with chronic heart failure PU
19/12 Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution EQ
19/12 Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution EQ
12/12 Bayer : Aflibercept 8 mg recommended for EU approval for third retinal indication PU
09/12 Bayer : AskBio’s AB-1005 and AB-1002 Receive Pioneering Regenerative Medical Product Designation in Japan PU
05/12 Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution EQ
04/12 Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution EQ
No results for this search